author-photo

Giraldo Kato

Pinnacle Financial Partners

4

Papers

223

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

2020 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (125)
Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (94)
Abstract P6-03-01: A phase Ib study of the CXCR1/2 inhibitor reparixin in combination with weekly paclitaxel in metastatic HER2 negative breast cancer – First analysis

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
Abstract C22: A phase Ib study of the CXCR1/2 inhibitor Reparixin in combination with weekly paclitaxel in metastatic HER2 negative breast cancer - final analysis

2015 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (1)